Search Results
Dec 11, 2025, 16:50 ET NOTICE OF SETTLEMENT APPROVAL ITHACA ENERGY INC. now known as ITHACA ENERGY LIMITED SECURITIES CLASS ACTION SECURITIES CLASS ACTION
PC as the Administrator of the settlement to, among other things: (i) receive and process Claim Forms; (ii) decide eligibility for compensation; and (iii) distribute the net Settlement Amount to eligible Class Members. The Claim Form should be submitted to the Administrator by using the secure Online Claims
More news about: Berger Montague
Dec 11, 2025, 15:05 ET The Generation Essentials Group
(the "Class A Ordinary Shares"); (ii) 4,285,911 Class B ordinary shares, each carrying twenty votes (the "Class B Ordinary Shares"), and (iii) 6,343,056 non-voting redeemable preferred shares (the "Preferred Shares"), in each case, with a par value of US$0.0000000264856557377049 per
More news about: The Generation Essentials Group
Dec 11, 2025, 13:05 ET Timeless Brands anuncia la apertura del primer MONOPOLY Steakhouse del mundo en San Pedro Garza García
audiencias locales. Sus divisiones incluyen: (i) Proyectos LBE + FEC (Centros de Entretenimiento Familiar), (ii) Representación de marcas globales y (iii) Consultoría estratégica para proyectos de entretenimiento y hospitalidad.Acerca de VXT CapitalVXT Capital es una firma mexicana
More news about: Timeless Brands
Dec 11, 2025, 12:26 ET HIRO Capital begrüßt Sir Nick Clegg als General Partner und lanciert europäischen Scale-up-Risikokapitalfonds HIRO III mit neuem Beirat aus globalen Führungspersönlichkeiten, darunter Yann LeCun
Global Affairs bei META und ehemaliger stellvertretender britischer Premierminister, dem Fonds als General Partner für den Start von HIRO III beigetreten ist. HIRO III ist ein großer Multi-Stage-Fonds, der jeweils zwischen 5 Mio. und 50 Mio. Euro in vielversprechende Innovatoren investieren kann und die
More news about: HIRO Capital
Dec 11, 2025, 11:00 ET Harris | Oakmark expands active ETF suite targeting international and global value opportunities
portfolio managers based on the managers' (i) "ability to generate exceptional returns; (ii) willingness to align their interests with shareholders; and (iii) courage to stay with their strategies in order to produce superior risk-adjusted returns in the end."Morningstar content: ©2025 Morningstar,
More news about: Harris | Oakmark
Dec 11, 2025, 10:00 ET Kessler Topaz Meltzer & Check, LLP Announces Proposed Settlement of the SEB Investment Management AB v. Wells Fargo & Company Securities Action
3:22-cv-03811-TLTSUMMARY NOTICE OF (I) PROPOSED SETTLEMENT; (II) SETTLEMENT HEARING; AND (III) MOTION FOR ATTORNEYS' FEES AND LITIGATION EXPENSES
More news about: Kessler Topaz Meltzer & Check, LLP
Dec 11, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Cepton, Inc. and Certain Officers - CPTN
meaningfully explore the foregoing offer and failed to disclose its terms when recommending that Cepton's shareholders approve the Koito Acquisition; (iii) consequently, Cepton's shareholders were deprived of the opportunity to meaningfully consider whether to accept or reject the Koito Acquisition; and
More news about: Pomerantz LLP
Dec 11, 2025, 09:29 ET The PHERGuide study demonstrates the utility of circulating tumor DNA for the early detection and real-time monitoring of localized HER2+ breast cancer
growing role of translational research in the advancement towards precision oncology that improves the patients' quality of life.The Phase III ADELA and TUXEDO-3 studies, also present at SABCS 2025The company has also presented a poster in a highlighted session regarding a sub-analysis
More news about: MEDSIR
Dec 11, 2025, 09:15 ET LGHL Announces Acquisition of Bitcoin Following the Subsequent Closing under $600 Million Facility
that offers a wide spectrum of products and services, including (i) total return swap (TRS) trading, (ii) contract-for-difference (CFD) trading, and (iii) Over-the-counter (OTC) stock options trading. Additional information may be found at http://ir.liongrouphl.com.Forward-Looking
More news about: Lion Group Holding Ltd.
Dec 11, 2025, 09:00 ET Lost Money on Skye Bioscience, Inc. (SKYE)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
effective than defendants had led investors to believe; (ii) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.DEADLINE: January 16, 2026 Shareholders
More news about: The Gross Law Firm
Dec 11, 2025, 09:00 ET DEFT LAWSUIT ALERT: The Gross Law Firm Notifies DeFi Technologies Investors of a Class Action Lawsuit and Upcoming Deadline
treasury companies and the extent to which that competition would negatively impact its ability to execute its DeFi arbitrage strategy; (iii) as a result of the foregoing issues, the Company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025; (iv) accordingly,
More news about: The Gross Law Firm
Dec 11, 2025, 09:00 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 26, 2025 in DexCom, Inc. Lawsuit - DXCM
and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (iv) defendants
More news about: The Gross Law Firm
Dec 11, 2025, 09:00 ET Shareholders that lost money on Firefly Aerospace Inc.(FLY) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
for its Spacecraft Solutions offerings; (ii) Firefly had overstated the operational readiness and commercial viability of its Alpha rocket program; (iii) the foregoing, once revealed, would likely have a material negative impact on the Company; and (iv) as a result, the offering documents and defendants'
More news about: The Gross Law Firm
Dec 11, 2025, 09:00 ET Five Leading Cancer Centers Unite to Target CD123 and Eradicate Hidden Leukemia Cells
extraordinary challenge pledge of $250 million from Mr. and Mrs. William H. Goodwin, Jr. and their family, and the estate of William Hunter Goodwin III.For further information, please visit the Foundation's website at
More news about: Break Through Cancer
Dec 11, 2025, 08:13 ET EQT exits remaining stake in Kodiak Gas Services, a leading provider of natural gas contract compression services in the United States
NEW YORK, Dec. 11, 2025 /PRNewswire/ -- EQT is pleased to announce that the EQT Infrastructure III and EQT Infrastructure IV funds ("EQT") have fully exited their investment in Kodiak Gas Services (NYSE: KGS, "Kodiak" or the "Company"). The exit marks
More news about: EQT
Dec 11, 2025, 08:11 ET EQT exits remaining stake in Kodiak Gas Services, a leading provider of natural gas contract compression services in the United States
YORK, Dec. 11, 2025 /PRNewswire/ -- EQT is pleased to announce that the EQT Infrastructure III and EQT Infrastructure IV funds ("EQT") have fully exited their investment in Kodiak Gas Services (NYSE: KGS, "Kodiak" or the "Company"). The exit marks
More news about: EQT
Dec 11, 2025, 06:00 ET IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
enrollment achievements, regulatory updates, clinical trial data readouts; (ii) the potential for an accelerated and full approval for darovasertib; (iii) the potential therapeutic benefit of darovasertib, including in combination with crizotinib; and (iv) the timing of development and regulatory milestones.
More news about: IDEAYA Biosciences, Inc.
Dec 11, 2025, 03:57 ET All change: Argus looks at the stresses in commodities markets for 2026
e-SAF.BIOFUELS markets could be disrupted by the uneven application of differing regimes across Europe — the EU's new RED III renewable energy directive is supposed to go live in a couple of weeks, but member governments, including in Europe's biggest biofuels markets, Germany
More news about: Argus Media
Dec 11, 2025, 01:04 ET Tejas Networks emerges as a leading supplier of IP Routing products across the country for BharatNet Phase III packages
(BSE: 540595) (NSE: TEJASNET) today announced that the company has been awarded IP Routing equipment purchase contracts for 7 of the 12 BharatNet Phase-III packages announced till date, thereby emerging as the largest supplier by the number of packages.
More news about: Tejas Networks
Dec 10, 2025, 20:53 ET Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). Currently, the multicenter, randomized, double-blind Phase III clinical trial (HARMONi-BC1/AK112-308) for this indication is currently ongoing.Preliminary results from this study were previously announced
More news about: Akeso, Inc.
Dec 10, 2025, 18:30 ET Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
CLDN18.2-positive, HER2-negative, PD-L1-positive locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma in the investigational Phase III LUCERNA study. For more information, visit clinicaltrials.gov with identifier
More news about: Astellas Pharma Inc.
Dec 10, 2025, 17:31 ET Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight
isoforms, it suppresses both mutant cancer-driving and cooperating wild-type RAS proteins. The therapy is currently under investigation in the Phase III RASolute-302 trial (NCT06625320) for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), with results anticipated in 2026.BioNTech/Genentech's
More news about: DelveInsight Business Research, LLP
Dec 10, 2025, 16:30 ET Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing,
More news about: Citius Oncology, Inc.
Dec 10, 2025, 16:05 ET Synopsys Posts Financial Results for Fourth Quarter and Fiscal Year 2025
exercise of the related stock-based awards and, therefore, is not used by management to assess the core profitability of our business operations.(iii) Acquisition/divestiture related items. In connection with certain of our business combinations and/or divestitures, we incur significant expenses
More news about: Synopsys, Inc.
Dec 10, 2025, 16:02 ET Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2026
release, we expect volatility in project delivery timelines for the balance of the fiscal year and we saw that begin in quarter 2," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "Our quoting and booking activity remain strong, which is reflected in our backlog that remains near
More news about: Kewaunee Scientific Corporation